AbCellera Biologics Inc.
About AbCellera Biologics Inc.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $75.1M
- Net income
- -$146.4M
- Total assets
- $1.4B
- Market cap
- $1.7B
- Operating margin
- -289.0%
- Net margin
- -194.9%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $75.1M
- Operating expenses
- $292.2M
- Operating income
- -$217.1M
- Income tax
- -$31.2M
- Net income
- -$146.4M
- EPS (basic)
- $-0.49
- EPS (diluted)
- $-0.49
Balance sheet
- Total assets
- $1.4B
- Current assets
- $728.2M
- Total liabilities
- $390.0M
- Current liabilities
- $64.3M
- Shareholders’ equity
- $966.9M
Cash flow
- Operating cash flow
- -$131.3M
- Investing cash flow
- $87.8M
- Financing cash flow
- $14.1M
- Net cash flow
- -$28.4M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $1.7B
- EPS (diluted)
- $-0.49
- Shares outstanding
- 316.6M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Dec 11, 2020
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $146.4M in FY2025.
- Revenue declined 80% from FY2021 to FY2025.
- Trading 16% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review AbCellera Biologics Inc..
Write a review
News about AbCellera Biologics Inc.
News & sentiment via Polygon.io
